董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Eric Sherb | 男 | Chief Financial Officer and Director | 38 | 未披露 | 未持股 | 2026-03-27 |
| Prashant Patel | 男 | Chairman and Chief Executive Officer | 51 | 未披露 | 未持股 | 2026-03-27 |
| Donald G. Fell | 男 | Independent Director | 79 | 未披露 | 未持股 | 2026-03-27 |
| Avinash Wadhwani | 男 | Independent Director | 57 | 未披露 | 未持股 | 2026-03-27 |
| Mayur Doshi | 男 | Independent Director | 63 | 未披露 | 未持股 | 2026-03-27 |
| Michael L. Peterson | 男 | Independent Director | 63 | 未披露 | 未持股 | 2026-03-27 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Eric Sherb | 男 | Chief Financial Officer and Director | 38 | 未披露 | 未持股 | 2026-03-27 |
| Prashant Patel | 男 | Chairman and Chief Executive Officer | 51 | 未披露 | 未持股 | 2026-03-27 |
董事简历
中英对照 | 中文 | 英文- Eric Sherb
-
Eric Sherb自2025年5月起担任Roze AI Inc. 首席财务官。注册会计师，16年会计咨询、审计、并购经验。Sherb先生目前担任SMC Entertainment Inc.（OTC：SMCE）、Scienture Holdings，Inc.（NASDAQ：SCNX）和Fatpipe Inc.（NASDAQ：FATN）的首席财务官。Sherb先生的职业生涯始于纽约市的普华永道会计师事务所，从对冲基金到制造业和医疗保健等多个行业（2008年7月至2013年1月）。在普华永道任职后，Sherb先生曾担任RBSM LLP的审计经理（2013年1月至2015年1月）和CFGI的高级经理（2015年3月至2018年10月）。自2018年10月以来，Sherb先生一直是EMS Consulting Services，LLC的创始人和所有者。Sherb先生在资本市场的财务报告和治理方面拥有丰富的经验，包括IPO、直接上市、SPAC和de SPAC交易。他曾担任首席财务官，并为多个纳斯达克和场外交易客户提供财务顾问服务，最近一次是。
Eric Sherb has served as Roze AI Inc. Chief Financial Officer since May 2025. He is a CPA with 16 years of experience in accounting advisory, auditing and mergers and acquisitions. Mr. Sherb currently serves as the Chief Financial Officer for SMC Entertainment Inc. (OTC: SMCE), Scienture Holdings, Inc. (NASDAQ: SCNX) and Fatpipe Inc. (NASDAQ: FATN). Mr. Sherb began his career at PricewaterhouseCoopers in New York City in a variety of industries from hedge funds to manufacturing and healthcare (July 2008 to January 2013). Following his time at PricewaterhouseCoopers, Mr. Sherb served as Audit Manager at RBSM LLP (January 2013 to January 2015), and Senior Manager at CFGI (March 2015 to October 2018). Since October 2018, Mr. Sherb has been a founder and owner of EMS Consulting Services, LLC. Mr. Sherb has extensive experience in financial reporting and governance within the capital markets, including IPOs, direct listings, SPAC and de SPAC transactions. He has served as chief financial officer and provided financial consultancy services for several NASDAQ and OTC clients, most recently. - Eric Sherb自2025年5月起担任Roze AI Inc. 首席财务官。注册会计师，16年会计咨询、审计、并购经验。Sherb先生目前担任SMC Entertainment Inc.（OTC：SMCE）、Scienture Holdings，Inc.（NASDAQ：SCNX）和Fatpipe Inc.（NASDAQ：FATN）的首席财务官。Sherb先生的职业生涯始于纽约市的普华永道会计师事务所，从对冲基金到制造业和医疗保健等多个行业（2008年7月至2013年1月）。在普华永道任职后，Sherb先生曾担任RBSM LLP的审计经理（2013年1月至2015年1月）和CFGI的高级经理（2015年3月至2018年10月）。自2018年10月以来，Sherb先生一直是EMS Consulting Services，LLC的创始人和所有者。Sherb先生在资本市场的财务报告和治理方面拥有丰富的经验，包括IPO、直接上市、SPAC和de SPAC交易。他曾担任首席财务官，并为多个纳斯达克和场外交易客户提供财务顾问服务，最近一次是。
- Eric Sherb has served as Roze AI Inc. Chief Financial Officer since May 2025. He is a CPA with 16 years of experience in accounting advisory, auditing and mergers and acquisitions. Mr. Sherb currently serves as the Chief Financial Officer for SMC Entertainment Inc. (OTC: SMCE), Scienture Holdings, Inc. (NASDAQ: SCNX) and Fatpipe Inc. (NASDAQ: FATN). Mr. Sherb began his career at PricewaterhouseCoopers in New York City in a variety of industries from hedge funds to manufacturing and healthcare (July 2008 to January 2013). Following his time at PricewaterhouseCoopers, Mr. Sherb served as Audit Manager at RBSM LLP (January 2013 to January 2015), and Senior Manager at CFGI (March 2015 to October 2018). Since October 2018, Mr. Sherb has been a founder and owner of EMS Consulting Services, LLC. Mr. Sherb has extensive experience in financial reporting and governance within the capital markets, including IPOs, direct listings, SPAC and de SPAC transactions. He has served as chief financial officer and provided financial consultancy services for several NASDAQ and OTC clients, most recently.
- Prashant Patel
-
Prashant Patel，自Trxade Health，Inc.于2014年1月8日收购TRxADE Nevada以来，一直担任Trxade Health，Inc.的全职总裁兼首席运营官和董事。帕特尔先生是一名注册药剂师和制药顾问，在零售药房和医药物流领域拥有20多年的经验，是佛罗里达州坦帕湾地区几家药房的创始人。Patel先生自2010年8月起担任Trxade Nevada总裁兼董事会成员。自2008年10月以来，帕特尔先生一直担任制药公司APAA LLC的管理成员和制药逆向分销商Pharmaceutical Returns Of America LLC的首席执行官。Patel先生毕业于诺丁汉大学药学院，在联合王国执业，之后在联合王国城市大学卡斯商学院获得运输、贸易和金融硕士学位。
Prashant Patel has served as a member of the Board of Directors of the Company since 2022 and was re appointed as President of the Company effective October 3, 2025, having previously served as Chief Strategy Officer and Vice Chairman of the Board until his resignation on August 8, 2025. Mr. Patel served on the board of Scienture from its acquisition of TRxADE Group, Inc., a Nevada corporation, on January 8, 2014, until January 16, 2025. He is an entrepreneur and a registered pharmacist with experience in multiple aspects of the pharmaceutical supply chain. He started several startups including retail and community pharmacy before expanding into pharmaceutical distribution and sales, focusing on pharmaceutical disposal and reverse distribution. He has also been a consultant to several return logistics pharmaceutical companies over the years. Mr. Patel possesses an excellent vision to has transparency, efficiency and cost benefits to US pharmaceutical channel partners. After graduating with a BPharm from the University of Nottingham, UK, Mr. Patel completed an MSc in Transport, Trade and Finance from Cass Business School, City University, UK. Mr. Patel is not independent as a result of his position as President of the Company. - Prashant Patel，自Trxade Health，Inc.于2014年1月8日收购TRxADE Nevada以来，一直担任Trxade Health，Inc.的全职总裁兼首席运营官和董事。帕特尔先生是一名注册药剂师和制药顾问，在零售药房和医药物流领域拥有20多年的经验，是佛罗里达州坦帕湾地区几家药房的创始人。Patel先生自2010年8月起担任Trxade Nevada总裁兼董事会成员。自2008年10月以来，帕特尔先生一直担任制药公司APAA LLC的管理成员和制药逆向分销商Pharmaceutical Returns Of America LLC的首席执行官。Patel先生毕业于诺丁汉大学药学院，在联合王国执业，之后在联合王国城市大学卡斯商学院获得运输、贸易和金融硕士学位。
- Prashant Patel has served as a member of the Board of Directors of the Company since 2022 and was re appointed as President of the Company effective October 3, 2025, having previously served as Chief Strategy Officer and Vice Chairman of the Board until his resignation on August 8, 2025. Mr. Patel served on the board of Scienture from its acquisition of TRxADE Group, Inc., a Nevada corporation, on January 8, 2014, until January 16, 2025. He is an entrepreneur and a registered pharmacist with experience in multiple aspects of the pharmaceutical supply chain. He started several startups including retail and community pharmacy before expanding into pharmaceutical distribution and sales, focusing on pharmaceutical disposal and reverse distribution. He has also been a consultant to several return logistics pharmaceutical companies over the years. Mr. Patel possesses an excellent vision to has transparency, efficiency and cost benefits to US pharmaceutical channel partners. After graduating with a BPharm from the University of Nottingham, UK, Mr. Patel completed an MSc in Transport, Trade and Finance from Cass Business School, City University, UK. Mr. Patel is not independent as a result of his position as President of the Company.
- Donald G. Fell
-
Donald G. Fell自2014年1月起担任公司独立董事。Fell先生还曾担任SPAC的董事。Kernel Group Holdings, Inc.（纳斯达克股票代码：KRNL）自2022年12月起担任SPAC的董事。OceanTech Acquisitions I Corp.丨OTEC（纳斯达克股票代码：TERM3）自2023年3月起担任董事，以及SPAC的Integrated Wellness Acquisition Corp（纽约证券交易所股票代码：WEL）的董事，自2024年2月起担任。Fell先生于2021年6月至2023年2月完成初始业务合并期间，曾担任SPAC旗下Aesther Healthcare Acquisition Corp.（n/k/a Ocean Biomedical, Inc.（纳斯达克股票代码：TERM1））的董事。Fell先生于2023年6月至2024年2月完成初始业务合并期间担任SPAC旗下Semper Paratus Acquisition Corporation（n/k/a Tevogen Bio Holdings Inc.（NASDAQ：TVGN））的董事。Fell先生于2023年8月至2025年2月完成初始业务合并之前，曾担任SPAC旗下PowerUp Acquisition Corp.（NASDAQ：PWUP）的董事。他目前是位于加利福尼亚州戴维斯的经济学教学基金会的教授和研究所所长，以及科罗拉多大学科罗拉多斯普林斯分校的经济学兼职教授。1995 – 2012年，Fell先生在南佛罗里达大学任职，担任执行MBA教员、执行和专业教育主任以及公共政策研究所高级研究员。他还曾担任法国拉罗谢尔大学经济学客座教授，同时担任伊利诺伊州立大学和俄亥俄州立大学经济学兼职教授。Fell先生拥有印第安纳州立大学的经济学本科和研究生学位，并且几乎是伊利诺伊州立大学的经济学学位论文（ABD）。通过与教授经济学基金会和科罗拉多大学科罗拉多斯普林斯分校的合作，他在44个州、遍布加拿大、群岛和东欧的经济政策和环境经济学研究生院进行了研究。
Donald G. Fell has served as an independent director of company since January 2014. Mr. Fell has also served as a director of Kernel Group Holdings, Inc. (NASDAQ: KRNL), a SPAC, since December 2022, served as a director of Oceantech Acquisitions I Corp. (NASDAQ: OTEC), a SPAC, since March 2023, and served as a director of Integrated Wellness Acquisition Corp (NYSE: WEL), a SPAC, since February 2024. Mr. Fell served as a director of Aesther Healthcare Acquisition Corp. (n/k/a Ocean Biomedical, Inc. (NASDAQ: OCEA)), a SPAC, from June 2021 until the completion of its initial business combination in February 2023. Mr. Fell served as a director of Semper Paratus Acquisition Corporation (n/k/a Tevogen Bio Holdings Inc. (NASDAQ: TVGN)), a SPAC, from June 2023 until the completion of its initial business combination in February 2024. Mr. Fell served as a director of PowerUp Acquisition Corp. (NASDAQ: PWUP), a SPAC, from August 2023 until the completion of its initial business combination in February 2025.He is presently Professor and Institute Director for the Davis, California based Foundation for Teaching Economics and adjunct professor of economics for the University of Colorado, Colorado, Springs. From 1995 – 2012, Mr. Fell held positions with the University of South Florida as a member of the Executive MBA faculty, Director of Executive and Professional Education, and Senior Fellow of the Public Policy Institute. He has also served as a visiting professor of economics at the University of LaRochelle, France, and as an adjunct professor of economics at both Illinois State University and The Ohio State University. Mr. Fell holds undergraduate and graduate degrees in economics from Indiana State University and is all but dissertation (ABD) in economics from Illinois State University. Through his work with the Foundation for Teaching Economics and the University of Colorado, Colorado Springs, he has conducted graduate institutes on economic policy and environmental economics in 44 states, throughout Canada, the Islands, and Eastern Europe. - Donald G. Fell自2014年1月起担任公司独立董事。Fell先生还曾担任SPAC的董事。Kernel Group Holdings, Inc.（纳斯达克股票代码：KRNL）自2022年12月起担任SPAC的董事。OceanTech Acquisitions I Corp.丨OTEC（纳斯达克股票代码：TERM3）自2023年3月起担任董事，以及SPAC的Integrated Wellness Acquisition Corp（纽约证券交易所股票代码：WEL）的董事，自2024年2月起担任。Fell先生于2021年6月至2023年2月完成初始业务合并期间，曾担任SPAC旗下Aesther Healthcare Acquisition Corp.（n/k/a Ocean Biomedical, Inc.（纳斯达克股票代码：TERM1））的董事。Fell先生于2023年6月至2024年2月完成初始业务合并期间担任SPAC旗下Semper Paratus Acquisition Corporation（n/k/a Tevogen Bio Holdings Inc.（NASDAQ：TVGN））的董事。Fell先生于2023年8月至2025年2月完成初始业务合并之前，曾担任SPAC旗下PowerUp Acquisition Corp.（NASDAQ：PWUP）的董事。他目前是位于加利福尼亚州戴维斯的经济学教学基金会的教授和研究所所长，以及科罗拉多大学科罗拉多斯普林斯分校的经济学兼职教授。1995 – 2012年，Fell先生在南佛罗里达大学任职，担任执行MBA教员、执行和专业教育主任以及公共政策研究所高级研究员。他还曾担任法国拉罗谢尔大学经济学客座教授，同时担任伊利诺伊州立大学和俄亥俄州立大学经济学兼职教授。Fell先生拥有印第安纳州立大学的经济学本科和研究生学位，并且几乎是伊利诺伊州立大学的经济学学位论文（ABD）。通过与教授经济学基金会和科罗拉多大学科罗拉多斯普林斯分校的合作，他在44个州、遍布加拿大、群岛和东欧的经济政策和环境经济学研究生院进行了研究。
- Donald G. Fell has served as an independent director of company since January 2014. Mr. Fell has also served as a director of Kernel Group Holdings, Inc. (NASDAQ: KRNL), a SPAC, since December 2022, served as a director of Oceantech Acquisitions I Corp. (NASDAQ: OTEC), a SPAC, since March 2023, and served as a director of Integrated Wellness Acquisition Corp (NYSE: WEL), a SPAC, since February 2024. Mr. Fell served as a director of Aesther Healthcare Acquisition Corp. (n/k/a Ocean Biomedical, Inc. (NASDAQ: OCEA)), a SPAC, from June 2021 until the completion of its initial business combination in February 2023. Mr. Fell served as a director of Semper Paratus Acquisition Corporation (n/k/a Tevogen Bio Holdings Inc. (NASDAQ: TVGN)), a SPAC, from June 2023 until the completion of its initial business combination in February 2024. Mr. Fell served as a director of PowerUp Acquisition Corp. (NASDAQ: PWUP), a SPAC, from August 2023 until the completion of its initial business combination in February 2025.He is presently Professor and Institute Director for the Davis, California based Foundation for Teaching Economics and adjunct professor of economics for the University of Colorado, Colorado, Springs. From 1995 – 2012, Mr. Fell held positions with the University of South Florida as a member of the Executive MBA faculty, Director of Executive and Professional Education, and Senior Fellow of the Public Policy Institute. He has also served as a visiting professor of economics at the University of LaRochelle, France, and as an adjunct professor of economics at both Illinois State University and The Ohio State University. Mr. Fell holds undergraduate and graduate degrees in economics from Indiana State University and is all but dissertation (ABD) in economics from Illinois State University. Through his work with the Foundation for Teaching Economics and the University of Colorado, Colorado Springs, he has conducted graduate institutes on economic policy and environmental economics in 44 states, throughout Canada, the Islands, and Eastern Europe.
- Avinash Wadhwani
-
Avinash Wadhwani目前是TransForm Solution Inc.的执行副总裁兼战略顾问，该公司是一家业务流程外包（BPO）公司，专门从事分析、数字干预和运营管理，他自2023年5月起担任该职务。从2009年4月至2020年4月，Wadhwani先生在价值数十亿美元的IT服务和咨询公司高知特（“高知特”）任职，结束了在高知特担任资本市场与投资银行业务副总监的任期。Wadhwani先生于2003年至2005年在Headstrong（现为简柏特（NYSE：G））担任业务发展—银行与资本市场高级经理，并于1999年至2002年在Polaris Software Services担任助理副总裁。在印度，Wadhwani先生曾于1994年至1999年在Daewoo Finance（India）Ltd.担任机构股票销售主管，并于1991年至1994年在Tata Consultancy Services担任产品营销和销售主管。在他的整个职业生涯中，Wadhwani先生在金融服务、零售和媒体与娱乐行业谈判并达成了几项多年、数百万美元的全球技术服务交易。他是一家基于SaaS的区块链初创公司的联合创始人，他在从头开始的概念化、架构和构建方面发挥了重要作用。Wadhwani先生带来了在初创公司、成长阶段组织和财富500强公司工作的经验。他是Semper Paratus Acquisition Corp（NASDAQ：LGST）的董事会成员，也是一家总部位于美国的非营利组织Quench and Nourish的董事会成员。Wadhwani先生获得了孟买大学的计算机科学学位和市场营销硕士学位。他拥有纽约市哥伦比亚商学院的MBA（行政）学位。
Avinash Wadhwani serves as a director. He is currently Executive Vice President and Strategic Advisor of TransForm Solution Inc. since May 2023. From May 2020 to April 2023, Mr. Wadhwani co founded a SaaS based blockchain startup. From April 2009 to April 2020, Mr. Wadhwani held positions at Cognizant Technology Solutions, ending his tenure as Assoc. Director, Capital Markets & Investment Banking. He previously served on the board of Semper Paratus Acquisition Corporation (n/k/a Tevogen Bio Holdings Inc. (NASDAQ: TVGN)). Mr. Wadhwani earned a degree in Computer Science and a Masters in Marketing from the University of Mumbai, and holds an MBA (Executive) from Columbia Business School. - Avinash Wadhwani目前是TransForm Solution Inc.的执行副总裁兼战略顾问，该公司是一家业务流程外包（BPO）公司，专门从事分析、数字干预和运营管理，他自2023年5月起担任该职务。从2009年4月至2020年4月，Wadhwani先生在价值数十亿美元的IT服务和咨询公司高知特（“高知特”）任职，结束了在高知特担任资本市场与投资银行业务副总监的任期。Wadhwani先生于2003年至2005年在Headstrong（现为简柏特（NYSE：G））担任业务发展—银行与资本市场高级经理，并于1999年至2002年在Polaris Software Services担任助理副总裁。在印度，Wadhwani先生曾于1994年至1999年在Daewoo Finance（India）Ltd.担任机构股票销售主管，并于1991年至1994年在Tata Consultancy Services担任产品营销和销售主管。在他的整个职业生涯中，Wadhwani先生在金融服务、零售和媒体与娱乐行业谈判并达成了几项多年、数百万美元的全球技术服务交易。他是一家基于SaaS的区块链初创公司的联合创始人，他在从头开始的概念化、架构和构建方面发挥了重要作用。Wadhwani先生带来了在初创公司、成长阶段组织和财富500强公司工作的经验。他是Semper Paratus Acquisition Corp（NASDAQ：LGST）的董事会成员，也是一家总部位于美国的非营利组织Quench and Nourish的董事会成员。Wadhwani先生获得了孟买大学的计算机科学学位和市场营销硕士学位。他拥有纽约市哥伦比亚商学院的MBA（行政）学位。
- Avinash Wadhwani serves as a director. He is currently Executive Vice President and Strategic Advisor of TransForm Solution Inc. since May 2023. From May 2020 to April 2023, Mr. Wadhwani co founded a SaaS based blockchain startup. From April 2009 to April 2020, Mr. Wadhwani held positions at Cognizant Technology Solutions, ending his tenure as Assoc. Director, Capital Markets & Investment Banking. He previously served on the board of Semper Paratus Acquisition Corporation (n/k/a Tevogen Bio Holdings Inc. (NASDAQ: TVGN)). Mr. Wadhwani earned a degree in Computer Science and a Masters in Marketing from the University of Mumbai, and holds an MBA (Executive) from Columbia Business School.
- Mayur Doshi
-
Mayur Doshi是AlfaGene Bioscience，Inc.的总裁兼首席执行官。他成功发起了几家公司，过去十年一直担任Apogee Pharma的首席执行官。他还于2023年8月至2025年2月期间担任特殊目的收购公司PowerUp Acquisition Corp.（NASDAQ：PWUP）的董事。他在全球仿制药市场拥有超过20年的经验。他是一位训练有素的化学家和经验丰富的企业家，在活性药物成分方面拥有丰富的经验。拥有20多年制药和生物技术行业经验，1988年进入仿制药行业。他是Apogee Pharma，Inc.的董事长兼董事总经理，Apogee Pharma，Inc.是应用程序编程接口（API）的主要进口商。他也是一家仿制药公司的主要投资者，是AlfaGene的创始人和主要投资者。他在制药行业广泛工作和管理，创建了一家价值数百万美元的公司。Doshi先生还担任各种组织的慈善家。
Mayur Doshi is President and Chief Executive Officer of AlfaGene Bioscience, Inc. He has successfully initiated several companies and for the last ten years has been the Chief Executive Officer of Apogee Pharma. He also served as a director of PowerUp Acquisition Corp. (NASDAQ: PWUP), a special purpose acquisition company, from August 2023 to February 2025. He has over 20 years of experience in the global generic pharmaceutical market. He is a trained chemist and seasoned entrepreneur with extensive experience in active pharmaceutical ingredients. He has more than 20 years of pharmaceutical and bio tech industry experience, entering the generic pharmaceutical industry in 1988. He is Chairman and Managing Director of Apogee Pharma, Inc., a major importer of application programming interfaces (APIs). He is also a major investor in a generic pharmaceutical company and is the founder of, and primary investor in, AlfaGene. He worked and managed extensively in the pharmaceutical industry and created a multimillion dollar company. Mr. Doshi also serves as a philanthropist for various organizations. - Mayur Doshi是AlfaGene Bioscience，Inc.的总裁兼首席执行官。他成功发起了几家公司，过去十年一直担任Apogee Pharma的首席执行官。他还于2023年8月至2025年2月期间担任特殊目的收购公司PowerUp Acquisition Corp.（NASDAQ：PWUP）的董事。他在全球仿制药市场拥有超过20年的经验。他是一位训练有素的化学家和经验丰富的企业家，在活性药物成分方面拥有丰富的经验。拥有20多年制药和生物技术行业经验，1988年进入仿制药行业。他是Apogee Pharma，Inc.的董事长兼董事总经理，Apogee Pharma，Inc.是应用程序编程接口（API）的主要进口商。他也是一家仿制药公司的主要投资者，是AlfaGene的创始人和主要投资者。他在制药行业广泛工作和管理，创建了一家价值数百万美元的公司。Doshi先生还担任各种组织的慈善家。
- Mayur Doshi is President and Chief Executive Officer of AlfaGene Bioscience, Inc. He has successfully initiated several companies and for the last ten years has been the Chief Executive Officer of Apogee Pharma. He also served as a director of PowerUp Acquisition Corp. (NASDAQ: PWUP), a special purpose acquisition company, from August 2023 to February 2025. He has over 20 years of experience in the global generic pharmaceutical market. He is a trained chemist and seasoned entrepreneur with extensive experience in active pharmaceutical ingredients. He has more than 20 years of pharmaceutical and bio tech industry experience, entering the generic pharmaceutical industry in 1988. He is Chairman and Managing Director of Apogee Pharma, Inc., a major importer of application programming interfaces (APIs). He is also a major investor in a generic pharmaceutical company and is the founder of, and primary investor in, AlfaGene. He worked and managed extensively in the pharmaceutical industry and created a multimillion dollar company. Mr. Doshi also serves as a philanthropist for various organizations.
- Michael L. Peterson
-
Michael L. Peterson，自2023年10月起担任Trio Petroleum Corp.首席执行官，自2022年7月起担任董事。他自2022年3月起担任Lafayette Energy Corporation的首席执行官，自2024年1月起担任Danam Health， Inc.（一家私营公司）的董事，自2021年1月起担任Integrated Wellness Acquisition Corp.（纳斯达克股票代码：WEL）的董事和Indonesia Energy Corporation（纽约证券交易所股票代码：INDO）的董事。自2016年8月以来，Peterson先生还担任TrxAde Group， Inc.（纳斯达克股票代码：MEDS）董事会的独立董事，这是一家总部位于佛罗里达州的基于网络的制药市场平台。在特殊目的收购公司的董事职位方面，他目前担任OceanTech Acquisitions I Corp（纳斯达克股票代码：OTEC）的董事（自2023年3月以来），Semper Paratus acquisition Corp（纳斯达克股票代码：LGST）的董事（自2023年5月以来），Powerup acquisition Corp（纳斯达克股票代码：PWUP）的董事（自2023年8月以来），在De-Spac的最后阶段都是SPAC。自2020年12月以来，他一直担任Nevo Motors， Inc.（一家将低碳排放卡车商业化的公司）的首席执行官。从2011年到2018年，Peterson先生担任PEDEVCO Corp.（纽约证券交易所美国股票代码：PED）的多个执行官职位，PEDEVCO Corp.是一家上市公司，主要从事美国石油和天然气页岩的收购、勘探、开发和生产。这些职位包括首席执行官、总裁、首席财务官和执行副总裁。从2006年到2012年，他曾担任Aemetis， Inc.（前身为AE biofuel Inc.）的多个高管职位，这是一家总部位于加州库比蒂诺的全球先进生物燃料和可再生商品化学品公司。这些职位包括临时总裁、董事和执行副总裁。从2008年12月到2012年7月，Peterson先生还担任Nevo Energy， Inc.（前身为Solargen Energy， Inc.）的董事长兼首席执行官，这是一家总部位于加州库比蒂诺的公用事业规模太阳能农场开发商，他帮助成立，目前作为Nevo Motors， Inc.运营。从2005年到2006年，Peterson先生担任American Institutional Partners的管理合伙人，这是一家总部位于Salt Lake City的风险投资基金。从2000年到2004年，他担任Merrill Lynch的第一副总裁，在那里他帮助建立了一个新的私人客户服务部门，专门与高净值投资者合作。从1989年9月到2000年1月，Peterson先生受雇于Goldman Sachs & Co.担任各种职位和角色，包括担任副总裁，负责一个专业团队，为超过70亿美元的资产提供建议和管理。自2018年从Pedevco退休以来，他一直担任the Church of Jesus Christ of Latter-day Saints台北台湾宣教会会长。他持有Marriott 管理学院的工商管理硕士学位，以及Brigham Young University的统计和计算机科学学士学位。
Michael L. Peterson serves as a director, chairman of compensation committee, and member of audit committee. Since January 2021, Mr. Peterson has served as a director of Indonesia Energy Corporation Limited (NYSE American: INDO). Mr. Peterson commenced serving as President, Chief Executive Officer and as a director of Lafayette Energy Corp. in April 2022. Mr. Peterson has served as a director of Kernel Group Holdings, Inc. (NASDAQ: KRNL) since December 2022, Oceantech Acquisitions I Corp. (NASDAQ: OTAC) since March 2023, and Integrated Wellness Acquisition Corp (OTC: WELNF) since February 2024. Mr. Peterson served as a director of Aesther Healthcare Acquisition Corp. (n/k/a Ocean Biomedical, Inc. (OTC: OCEA)) from June 2021 until the completion of its initial business combination in February 2023, and as a director of Semper Paratus Acquisition Corporation (n/k/a Tevogen Bio Holdings Inc. (NASDAQ: TVGN)) from June 2023 until the completion of its initial business combination in February 2024. Mr. Peterson also serves as a director of Wellgistics Health, Inc. since January 2024. He previously served as CEO of PEDEVCO Corp. (NYSE American: PED) from May 2016 to May 2018. Mr. Peterson received his MBA from the Marriott School of Management and a BS in statistics/computer science from Brigham Young University. - Michael L. Peterson，自2023年10月起担任Trio Petroleum Corp.首席执行官，自2022年7月起担任董事。他自2022年3月起担任Lafayette Energy Corporation的首席执行官，自2024年1月起担任Danam Health， Inc.（一家私营公司）的董事，自2021年1月起担任Integrated Wellness Acquisition Corp.（纳斯达克股票代码：WEL）的董事和Indonesia Energy Corporation（纽约证券交易所股票代码：INDO）的董事。自2016年8月以来，Peterson先生还担任TrxAde Group， Inc.（纳斯达克股票代码：MEDS）董事会的独立董事，这是一家总部位于佛罗里达州的基于网络的制药市场平台。在特殊目的收购公司的董事职位方面，他目前担任OceanTech Acquisitions I Corp（纳斯达克股票代码：OTEC）的董事（自2023年3月以来），Semper Paratus acquisition Corp（纳斯达克股票代码：LGST）的董事（自2023年5月以来），Powerup acquisition Corp（纳斯达克股票代码：PWUP）的董事（自2023年8月以来），在De-Spac的最后阶段都是SPAC。自2020年12月以来，他一直担任Nevo Motors， Inc.（一家将低碳排放卡车商业化的公司）的首席执行官。从2011年到2018年，Peterson先生担任PEDEVCO Corp.（纽约证券交易所美国股票代码：PED）的多个执行官职位，PEDEVCO Corp.是一家上市公司，主要从事美国石油和天然气页岩的收购、勘探、开发和生产。这些职位包括首席执行官、总裁、首席财务官和执行副总裁。从2006年到2012年，他曾担任Aemetis， Inc.（前身为AE biofuel Inc.）的多个高管职位，这是一家总部位于加州库比蒂诺的全球先进生物燃料和可再生商品化学品公司。这些职位包括临时总裁、董事和执行副总裁。从2008年12月到2012年7月，Peterson先生还担任Nevo Energy， Inc.（前身为Solargen Energy， Inc.）的董事长兼首席执行官，这是一家总部位于加州库比蒂诺的公用事业规模太阳能农场开发商，他帮助成立，目前作为Nevo Motors， Inc.运营。从2005年到2006年，Peterson先生担任American Institutional Partners的管理合伙人，这是一家总部位于Salt Lake City的风险投资基金。从2000年到2004年，他担任Merrill Lynch的第一副总裁，在那里他帮助建立了一个新的私人客户服务部门，专门与高净值投资者合作。从1989年9月到2000年1月，Peterson先生受雇于Goldman Sachs & Co.担任各种职位和角色，包括担任副总裁，负责一个专业团队，为超过70亿美元的资产提供建议和管理。自2018年从Pedevco退休以来，他一直担任the Church of Jesus Christ of Latter-day Saints台北台湾宣教会会长。他持有Marriott 管理学院的工商管理硕士学位，以及Brigham Young University的统计和计算机科学学士学位。
- Michael L. Peterson serves as a director, chairman of compensation committee, and member of audit committee. Since January 2021, Mr. Peterson has served as a director of Indonesia Energy Corporation Limited (NYSE American: INDO). Mr. Peterson commenced serving as President, Chief Executive Officer and as a director of Lafayette Energy Corp. in April 2022. Mr. Peterson has served as a director of Kernel Group Holdings, Inc. (NASDAQ: KRNL) since December 2022, Oceantech Acquisitions I Corp. (NASDAQ: OTAC) since March 2023, and Integrated Wellness Acquisition Corp (OTC: WELNF) since February 2024. Mr. Peterson served as a director of Aesther Healthcare Acquisition Corp. (n/k/a Ocean Biomedical, Inc. (OTC: OCEA)) from June 2021 until the completion of its initial business combination in February 2023, and as a director of Semper Paratus Acquisition Corporation (n/k/a Tevogen Bio Holdings Inc. (NASDAQ: TVGN)) from June 2023 until the completion of its initial business combination in February 2024. Mr. Peterson also serves as a director of Wellgistics Health, Inc. since January 2024. He previously served as CEO of PEDEVCO Corp. (NYSE American: PED) from May 2016 to May 2018. Mr. Peterson received his MBA from the Marriott School of Management and a BS in statistics/computer science from Brigham Young University.
高管简历
中英对照 | 中文 | 英文- Eric Sherb
Eric Sherb自2025年5月起担任Roze AI Inc. 首席财务官。注册会计师，16年会计咨询、审计、并购经验。Sherb先生目前担任SMC Entertainment Inc.（OTC：SMCE）、Scienture Holdings，Inc.（NASDAQ：SCNX）和Fatpipe Inc.（NASDAQ：FATN）的首席财务官。Sherb先生的职业生涯始于纽约市的普华永道会计师事务所，从对冲基金到制造业和医疗保健等多个行业（2008年7月至2013年1月）。在普华永道任职后，Sherb先生曾担任RBSM LLP的审计经理（2013年1月至2015年1月）和CFGI的高级经理（2015年3月至2018年10月）。自2018年10月以来，Sherb先生一直是EMS Consulting Services，LLC的创始人和所有者。Sherb先生在资本市场的财务报告和治理方面拥有丰富的经验，包括IPO、直接上市、SPAC和de SPAC交易。他曾担任首席财务官，并为多个纳斯达克和场外交易客户提供财务顾问服务，最近一次是。
Eric Sherb has served as Roze AI Inc. Chief Financial Officer since May 2025. He is a CPA with 16 years of experience in accounting advisory, auditing and mergers and acquisitions. Mr. Sherb currently serves as the Chief Financial Officer for SMC Entertainment Inc. (OTC: SMCE), Scienture Holdings, Inc. (NASDAQ: SCNX) and Fatpipe Inc. (NASDAQ: FATN). Mr. Sherb began his career at PricewaterhouseCoopers in New York City in a variety of industries from hedge funds to manufacturing and healthcare (July 2008 to January 2013). Following his time at PricewaterhouseCoopers, Mr. Sherb served as Audit Manager at RBSM LLP (January 2013 to January 2015), and Senior Manager at CFGI (March 2015 to October 2018). Since October 2018, Mr. Sherb has been a founder and owner of EMS Consulting Services, LLC. Mr. Sherb has extensive experience in financial reporting and governance within the capital markets, including IPOs, direct listings, SPAC and de SPAC transactions. He has served as chief financial officer and provided financial consultancy services for several NASDAQ and OTC clients, most recently.- Eric Sherb自2025年5月起担任Roze AI Inc. 首席财务官。注册会计师，16年会计咨询、审计、并购经验。Sherb先生目前担任SMC Entertainment Inc.（OTC：SMCE）、Scienture Holdings，Inc.（NASDAQ：SCNX）和Fatpipe Inc.（NASDAQ：FATN）的首席财务官。Sherb先生的职业生涯始于纽约市的普华永道会计师事务所，从对冲基金到制造业和医疗保健等多个行业（2008年7月至2013年1月）。在普华永道任职后，Sherb先生曾担任RBSM LLP的审计经理（2013年1月至2015年1月）和CFGI的高级经理（2015年3月至2018年10月）。自2018年10月以来，Sherb先生一直是EMS Consulting Services，LLC的创始人和所有者。Sherb先生在资本市场的财务报告和治理方面拥有丰富的经验，包括IPO、直接上市、SPAC和de SPAC交易。他曾担任首席财务官，并为多个纳斯达克和场外交易客户提供财务顾问服务，最近一次是。
- Eric Sherb has served as Roze AI Inc. Chief Financial Officer since May 2025. He is a CPA with 16 years of experience in accounting advisory, auditing and mergers and acquisitions. Mr. Sherb currently serves as the Chief Financial Officer for SMC Entertainment Inc. (OTC: SMCE), Scienture Holdings, Inc. (NASDAQ: SCNX) and Fatpipe Inc. (NASDAQ: FATN). Mr. Sherb began his career at PricewaterhouseCoopers in New York City in a variety of industries from hedge funds to manufacturing and healthcare (July 2008 to January 2013). Following his time at PricewaterhouseCoopers, Mr. Sherb served as Audit Manager at RBSM LLP (January 2013 to January 2015), and Senior Manager at CFGI (March 2015 to October 2018). Since October 2018, Mr. Sherb has been a founder and owner of EMS Consulting Services, LLC. Mr. Sherb has extensive experience in financial reporting and governance within the capital markets, including IPOs, direct listings, SPAC and de SPAC transactions. He has served as chief financial officer and provided financial consultancy services for several NASDAQ and OTC clients, most recently.
- Prashant Patel
Prashant Patel，自Trxade Health，Inc.于2014年1月8日收购TRxADE Nevada以来，一直担任Trxade Health，Inc.的全职总裁兼首席运营官和董事。帕特尔先生是一名注册药剂师和制药顾问，在零售药房和医药物流领域拥有20多年的经验，是佛罗里达州坦帕湾地区几家药房的创始人。Patel先生自2010年8月起担任Trxade Nevada总裁兼董事会成员。自2008年10月以来，帕特尔先生一直担任制药公司APAA LLC的管理成员和制药逆向分销商Pharmaceutical Returns Of America LLC的首席执行官。Patel先生毕业于诺丁汉大学药学院，在联合王国执业，之后在联合王国城市大学卡斯商学院获得运输、贸易和金融硕士学位。
Prashant Patel has served as a member of the Board of Directors of the Company since 2022 and was re appointed as President of the Company effective October 3, 2025, having previously served as Chief Strategy Officer and Vice Chairman of the Board until his resignation on August 8, 2025. Mr. Patel served on the board of Scienture from its acquisition of TRxADE Group, Inc., a Nevada corporation, on January 8, 2014, until January 16, 2025. He is an entrepreneur and a registered pharmacist with experience in multiple aspects of the pharmaceutical supply chain. He started several startups including retail and community pharmacy before expanding into pharmaceutical distribution and sales, focusing on pharmaceutical disposal and reverse distribution. He has also been a consultant to several return logistics pharmaceutical companies over the years. Mr. Patel possesses an excellent vision to has transparency, efficiency and cost benefits to US pharmaceutical channel partners. After graduating with a BPharm from the University of Nottingham, UK, Mr. Patel completed an MSc in Transport, Trade and Finance from Cass Business School, City University, UK. Mr. Patel is not independent as a result of his position as President of the Company.- Prashant Patel，自Trxade Health，Inc.于2014年1月8日收购TRxADE Nevada以来，一直担任Trxade Health，Inc.的全职总裁兼首席运营官和董事。帕特尔先生是一名注册药剂师和制药顾问，在零售药房和医药物流领域拥有20多年的经验，是佛罗里达州坦帕湾地区几家药房的创始人。Patel先生自2010年8月起担任Trxade Nevada总裁兼董事会成员。自2008年10月以来，帕特尔先生一直担任制药公司APAA LLC的管理成员和制药逆向分销商Pharmaceutical Returns Of America LLC的首席执行官。Patel先生毕业于诺丁汉大学药学院，在联合王国执业，之后在联合王国城市大学卡斯商学院获得运输、贸易和金融硕士学位。
- Prashant Patel has served as a member of the Board of Directors of the Company since 2022 and was re appointed as President of the Company effective October 3, 2025, having previously served as Chief Strategy Officer and Vice Chairman of the Board until his resignation on August 8, 2025. Mr. Patel served on the board of Scienture from its acquisition of TRxADE Group, Inc., a Nevada corporation, on January 8, 2014, until January 16, 2025. He is an entrepreneur and a registered pharmacist with experience in multiple aspects of the pharmaceutical supply chain. He started several startups including retail and community pharmacy before expanding into pharmaceutical distribution and sales, focusing on pharmaceutical disposal and reverse distribution. He has also been a consultant to several return logistics pharmaceutical companies over the years. Mr. Patel possesses an excellent vision to has transparency, efficiency and cost benefits to US pharmaceutical channel partners. After graduating with a BPharm from the University of Nottingham, UK, Mr. Patel completed an MSc in Transport, Trade and Finance from Cass Business School, City University, UK. Mr. Patel is not independent as a result of his position as President of the Company.